Navicixizumab is under clinical development by OncXerna Therapeutics and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Navicixizumab’s likelihood of approval (LoA) and phase transition for Breast Cancer took place on 08 May 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

In addition, the same event on 08 May 2021 increased Navicixizumab’s Phase Transition Success Rate (PTSR) for Pancreatic Cancer, increased PTSR for Uterine Cancer, and increased LoA and PTSR for Endometrial Cancer.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Navicixizumab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Navicixizumab overview

Navicixizumab (OMP-305B83) is under development for the treatment of platinum-resistant ovarian cancer, primary peritoneal, fallopian tube cancer and refractory solid tumors including breast cancer, pancreatic cancer, uterus cancer, lung cancer, endometrial cancer, gastric cancer, adenocarcinoma of the gastroesophageal junction, triple-negative breast cancer (TNBC) and uterine carcinosarcoma. It is administered intravenously. It is an anti-DLL4/VEGF bi-specific antibody. OMP-305B83 is a monoclonal antibody that targets both DLL4 and vascular endothelial growth factor. It is developed utilizing OncoMed's BiMAb technology platform. It was under development for solid tumors including metastatic colorectal cancer and uterine carcinosarcoma.

OncXerna Therapeutics overview

OncXerna Therapeutics is engaged in the development of state-of-the-art precision medicine for cancer patients and is also involved in discovering the dominant biology related characteristics in a person’s cancer at the RNA level to advance more meaningful treatments for more cancer patients. OncXerna Therapeutics is headquartered in Massachusetts, the US.

Quick View Navicixizumab LOA Data

Report Segments
  • Innovator
Drug Name
  • Navicixizumab
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.